Tumor Therapy of the Future
Four group heads from different departments across faculties have joined forces in a pioneering three-million franc project. This collaboration will enable research into new epigenetic approaches for treating cancer.
Acute myeloid leukemia (AML) is a dangerous cancer of the blood cells. Mutations in the blood-forming stem cells in the bone marrow lead to degeneration and the uncontrolled formation of abnormal cells. In many cases the only hope – if any at all – is a bone marrow transplant.
Now an interdisciplinary team of chemists, biochemists, geneticists and molecular biologists at UZH is going in search of new approaches to treating the disease. “The project is rooted in pure research and therefore risky,” explains Christian Mosimann, assistant professor at the IMLS (Institute of Molecular Life Sciences) and one of the four project heads. If it works, however, it could revolutionize the treatment of acute forms of leukemia.
Whatever the case, the Swiss National Science Foundation (SNSF) is convinced of the project’s merits and is funding the UZH research team to the tune of 3.2 million francs. One of the most persuasive attributes of the project was its cross-disciplinary approach, with different specialist disciplines in chemistry and molecular biology working together.
Unique combination of experts
The project involves two research groups under Cristina Nevado in chemistry and Amedeo Caflisch in biochemistry. They’re joined by epigeneticists in the group run by Tuncay Baubec (Department of Molecular Mechanisms of Disease) and developmental biologists from Christian Mosimann’s team. Together they’re addressing the question of how certain enzymes switch genes in the chromosome on and off.
“With this combination of specialists we can look into the questions that interest us from every level, from the structure of individual molecules to the entire organism,” says Cristina Nevado, professor of organic chemistry. She emphasizes that the project is only viable thanks to this unique combination of proven specialists. The group heads work at four different departments at the Faculty of Science, the Faculty of Medicine and the Vetsuisse Faculty.
In more specific terms, the project is looking into a class of enzymes with special structures called bromodomains, which enable them to chemically mark the DNA packed in the chromosomes or remove existing markers. With these epigenetic modifications they activate or deactivate the genes affected to regulate complex cell activity.
Errors in activation or deactivation are one of the reasons blood-forming stem cells start multiplying uncontrollably and form cancer cells in people with AML. There are also other cancers that involve epigenetic modifications. For this reason bromodomains are a way in for new types of therapy: If they’re blocked with small, synthetic molecules, the undesired gene regulation can be stopped.
To do this the chemists on the team will synthesize suitable inhibitors. The biochemists can test and refine their structural properties and ability to block bromodomains on the computer and in the test tube. Then come the epigeneticists with functional tests on embryo cells in mice. They’ll use genome-wide analysis to show how the inhibitors change epigenetic control.
Finally, the developmental biologists will investigate suitable lead substances to find out their effects on the blood-forming system of zebra fish, an important research model where each type of cell can be marked as desired and tracked microscopically from outside. Ultimately there should be promising active agents that can be tested on humans in more extensive clinical trials.
Epigenetics a hot topic
At least as important as developing new agents are the insights the research is expected to provide into gene regulation through the chemical modification of special proteins in the chromosomes. This area of epigenetic DNA control is still relatively young – and an absolute hot topic.
Epigenetics modulates gene activity and determines the effects of our genes on a second level in addition to heredity. Investigating the mechanisms of epigenetics is tantamount to exploring the primary gene effects which molecular biologists have been working on for decades.
After two years of planning by the group heads, the project kicked off only a short time ago with SNSF approval at the beginning of June. Recently around 20 researchers in the groups involved met to discuss the planned experiments. The mood is good, and after a time-consuming planning stage the experiments are set to begin. It’ll be exciting to see what this unique project will produce.
Stefan Stöcklin, Editor UZH News. English Translation by Philip Isler, UZH Communications.
Link to UZH press release in English
Link to UZH press release in German
- The Dutch Research Council (NOW) awarded a 2 year Rubicon grant to Dr. Yannick Kok for his project DNA repair: wrong place, wrong time
- Award Ceremony and Lectures Dr. Ernst Th. Jucker Preis 2019/2020 for Important Contributions to Cancer Research
- The project of the MSRU “Human-Horse Interaction” was awarded the “Prize for Educational Innovations” ”from the Hans-Peter Frey Foundation
- Kaivalya Walavalkar received the prestigious EMBO postdoctoral fellowship
- Scott Finlay PhD and Salim Darwiche PhD awarded first prize for best investor pitch, presenting their marketable product for cartilage repair
- Congratulations to SNSF Prof. Dr. Matthias Altmeyer for being appointed Associate Professor
- Congratulations to Prof.em. Dr. Brigitte von Rechenberg for obtaining ORS 2020 Women’s Leadership Forum Award
- Stephanie Lüthi receives semester price 2019 from VSF
- Prof. Dr. Tuncay Baubec receives ERC Consolidator Grant
- Ramon Pfändler receives semester price from MNF
- Nina Schmolka receives SNF Ambizione Fellowship
- New paper from group M. Altmeyer online in EMBO journal
- Molecular biologist Tuncay Baubec received the renowned Georg Friedrich Götz Award
- Preisgekrönte Nachwuchsforschung
- Verlängerung SNF Förderungsprofessur von Prof. Dr. Tuncay Baubec
- Erfolgsmeldung aus dem Department of Molecular Mechanisms of Disease
- Proteinveränderungen weisen auf Krebs hin
- Mass spectrometry method provides first view of stress-induced extracellular protein modification in cells and tissues
- Measuring the Effects of Drugs on Cancer Cells
- Prolongation of SNSF Professorship for Prof. Dr. Matthias Altmeyer
- Raffaella Santoro received the prestigious ERC advanced grant
- Article in UZH Magazin about Matthias Altmeyer on his work "Krebszellen im Burnout"
- Successful and stimulating 3rd Joint Department Colloquium (JDC) of the DMMD
- Important Mechanism of Epigenetic Gene Regulation Identified
- UZH press release on the work of Santoro and Cinelli groups on stem cell pluripotency in Nature Cell Biology
- Professorial appointment process successfully completed
- SNF Prof. Dr. Matthias Altmeyer receives highly prestigious ERC Starting Grant
- Dr. Francisco Verdeguer new group leader at DMMD
- Prof. Dr. Raffaella Santoro elected as new EMBO member
- Dr. Sandra Frommel from the Santoro group receives Jahrespreis of the Vetsuisse Faculty
- Group van Loon publishes on the impact of ribonucleotide incorporation on DNA base excision repair in Nature Communications
- Dr. Barbara van Loon appointed to Associate Professor position at the Norwegian University for Science and Technology
- IVBMB is now Department of Molecular Mechanisms of Disease (DMMD)
- Group Hottiger publishes on identification of genome-wide chromatin ADP-riboslyation in Molecular Cell
- Group Altmeyer publishes on intracellular phase separation in Nature Communications
- IVBMB now also associated with Faculty of Science (MNF)
- Dr. Tuncay Baubec awarded SNF-professorship to be carried out at the IVBMB
- Group Santoro awarded for Cell Stem Cell Cover Page
- Group Santoro publishes major study on predictive marker of prostate cancer recurrence in Nature Genetics
- Dr. Matthias Altmeyer awarded SNF-professorship to be carried out at the IVBMB
- Prof. Michael O. Hottiger new acting director of IVBMB as of 1. February 2014